Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease (MOMENTUM)

Investigator-initiated, Multicentre, International, Cross-sectional and Longitudinal Clinical Study Elucidating the Pathophysiology of Mild Cognitive Impairment in Chronic Kidney Disease With a Focus on the Role of Uremic Toxins

MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.

The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).

Studieoversikt

Detaljert beskrivelse

Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.

Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.

Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.

As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.

Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.

The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.

Studietype

Intervensjonell

Registrering (Antatt)

220

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Naples, Italia, 80131
    • BG
      • Ranica, BG, Italia, 24020
        • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
        • Ta kontakt med:
      • Pamplona, Spania, 31008
        • Clínica Universidad de Navarra
        • Ta kontakt med:
          • Nuria Garcia Fernandez, MD PhD
          • Telefonnummer: +34948255400
          • E-post: nrgarcia@unav.es
      • Derby, Storbritannia, DE22 3NE
        • University Hospitals of Derby and Burton NHS Foundation Trust
        • Ta kontakt med:
      • Lausanne, Sveits, 1005
        • Centre Hospitalier Universitaire Vaudois
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  • Male or female aged 40-75 years at time of screening;
  • Availability for longitudinal follow-up;
  • Signed informed consent

Specifically for CKD participants:

  • CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
  • MoCA score in the range [18-25];41

Specifically for controls:

  • Normal renal function:

    • For controls aged < 65 years, eGFR ≥ 90 mL/min/1.73 m2;
    • For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
  • No detectable proteinuria at screening (negative urine dipstick);

  • MoCA score ≥ 26/30.

Exclusion Criteria

  • Contraindication to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
  • Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
  • History of ischemic or hemorrhagic stroke and/or previous brain surgery;
  • History of severe traumatic brain injury;
  • Treated or untreated clinically significant depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
  • Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
  • Serious acute illness within the last 3 months;
  • Active solid tumors with or without metastasis;
  • Inflammatory bowel disease;
  • Systemic corticosteroid treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
  • Planned pregnancy during the 18-month follow-up period;

Specifically for CKD patients:

  • Peritoneal dialysis;
  • Kidney transplantation at enrolment;

Specifically for controls:

● Any chronic clinically significant condition, except for hypertension treated with < 3 antihypertensive drugs.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group 1

Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2)

Montreal Cognitive Assessment Test

The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling

MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)

The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)]

"Your Health" section, corresponding to the SF-12 questionnaire

Sections specific to kidney disease excluding the first section

Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq).

Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively.

Frailty will be evaluated using the Clinical Frailty Scale (CFS).

The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project

Eksperimentell: Group 2

Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR < 30 mL/min/1.73 m2)

Montreal Cognitive Assessment Test

The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling

MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)

The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)]

"Your Health" section, corresponding to the SF-12 questionnaire

Sections specific to kidney disease excluding the first section

Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq).

Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively.

Frailty will be evaluated using the Clinical Frailty Scale (CFS).

The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project

Eksperimentell: Group 3

Patients with CKD stage G5 on chronic hemodialysis (eGFR < 15 mL/min/1.73 m2)

Montreal Cognitive Assessment Test

The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling

MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)

The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)]

"Your Health" section, corresponding to the SF-12 questionnaire

Sections specific to kidney disease excluding the first section

Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq).

Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively.

Frailty will be evaluated using the Clinical Frailty Scale (CFS).

The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project

Eksperimentell: Group 4

Healthy controls

Montreal Cognitive Assessment Test

The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling

MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)

The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)]

"Your Health" section, corresponding to the SF-12 questionnaire

Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq).

Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively.

Frailty will be evaluated using the Clinical Frailty Scale (CFS).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
Tidsramme: Baseline (Visit 2, Day 0)

Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately.

Baseline (Visit 2, Day 0)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Norberto Perico, M.D., Istituto Di Ricerche Farmacologiche Mario Negri

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. april 2027

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere